CA2612672C - Traitement du dysfonctionnement sexuel - Google Patents

Traitement du dysfonctionnement sexuel Download PDF

Info

Publication number
CA2612672C
CA2612672C CA2612672A CA2612672A CA2612672C CA 2612672 C CA2612672 C CA 2612672C CA 2612672 A CA2612672 A CA 2612672A CA 2612672 A CA2612672 A CA 2612672A CA 2612672 C CA2612672 C CA 2612672C
Authority
CA
Canada
Prior art keywords
enantiomer
formula
sexual dysfunction
predominates
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2612672A
Other languages
English (en)
Other versions
CA2612672A1 (fr
Inventor
Joseph Palumbo
Johathan Sporn
Thomas Steckler
Yong Choi
James S. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA2612672A1 publication Critical patent/CA2612672A1/fr
Application granted granted Critical
Publication of CA2612672C publication Critical patent/CA2612672C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procédé de traitement de dysfonctionnement sexuel : administration de quantité thérapeutiquement efficace de composé de formule (I), y compris un sel ou ester correspondant pharmaceutiquement acceptable, sachant que Rx peut être hydrogène, alkyle inférieur avec 1 à 8 atomes de carbone, halogène comme F, CI, Br et I, alcoxy avec 1 à 3 atomes de carbone, nitro, hydroxy, trifluorométhyle, et thioalcoxy avec 1 à 3 atomes de carbone; x est un entier compris entre 1 et 3, à condition que R puisse être identique ou différent lorsque x vaut 2 ou 3; R1 et R2 peuvent être identiques ou différents et sont indépendamment hydrogène, alkyle inférieur avec 1 à 8 atomes de carbone, aryle, arylalkyle, cycloalkyle avec 3 à 7 atomes de carbone; R1 et R2 peuvent être assemblés pour former un hétérocycle avec 5 à 7 éléments, substitué avec un élément pouvant être hydrogène, alkyle, et groupes aryle, sachant que le composé cyclique peut comporter 1 ou 2 atomes d'azote et 0 ou 1 atome d'oxygène ; les atomes d'azote ne sont pas directement liés entre eux ou avec l'atome d'oxygène.
CA2612672A 2005-06-22 2006-06-13 Traitement du dysfonctionnement sexuel Expired - Fee Related CA2612672C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69280905P 2005-06-22 2005-06-22
US60/692,809 2005-06-22
PCT/US2006/023068 WO2007001841A1 (fr) 2005-06-22 2006-06-13 Traitement de dysfonctionnement sexuel

Publications (2)

Publication Number Publication Date
CA2612672A1 CA2612672A1 (fr) 2007-01-04
CA2612672C true CA2612672C (fr) 2014-10-14

Family

ID=37067408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2612672A Expired - Fee Related CA2612672C (fr) 2005-06-22 2006-06-13 Traitement du dysfonctionnement sexuel

Country Status (12)

Country Link
US (1) US8552060B2 (fr)
EP (1) EP1893291B1 (fr)
JP (1) JP5298334B2 (fr)
KR (1) KR101335942B1 (fr)
AR (1) AR054790A1 (fr)
AT (1) ATE459393T1 (fr)
CA (1) CA2612672C (fr)
DE (1) DE602006012670D1 (fr)
ES (1) ES2344469T3 (fr)
MY (1) MY145066A (fr)
TW (1) TWI387452B (fr)
WO (1) WO2007001841A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8895609B2 (en) * 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
EP4316592A3 (fr) 2016-10-06 2024-05-01 Axsome Malta Ltd. Composés de carbamoyl phénylalaninol et leurs utilisations
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260667A (en) * 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2587481A1 (fr) * 2004-10-28 2006-05-11 Sk Corporation Therapie d'adjuvants de carbamates phenylalkylamino pour la depression
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia

Also Published As

Publication number Publication date
TW200727893A (en) 2007-08-01
EP1893291A1 (fr) 2008-03-05
JP2008546778A (ja) 2008-12-25
US8552060B2 (en) 2013-10-08
TWI387452B (zh) 2013-03-01
DE602006012670D1 (de) 2010-04-15
EP1893291B1 (fr) 2010-03-03
JP5298334B2 (ja) 2013-09-25
US20090221553A1 (en) 2009-09-03
ES2344469T3 (es) 2010-08-27
ATE459393T1 (de) 2010-03-15
MY145066A (en) 2011-12-15
KR101335942B1 (ko) 2013-12-04
KR20080028445A (ko) 2008-03-31
AR054790A1 (es) 2007-07-18
CA2612672A1 (fr) 2007-01-04
WO2007001841A1 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
US11713292B2 (en) Treatment of cataplexy
CA2612672C (fr) Traitement du dysfonctionnement sexuel
US11753368B2 (en) Treatment of sleep-wake disorders
AU2010316172B2 (en) Methods for treating fibromyalgia syndrome
US8729120B2 (en) Adjunctive therapy for depression

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831